Rexahn Pharmaceuticals Stock Price, News & Analysis (NYSEAMERICAN:RNN)

$2.11 0.03 (1.44 %)
(As of 11/21/2017 03:10 AM ET)
Previous Close$2.08
Today's Range$2.00 - $2.12
52-Week Range$1.30 - $7.10
Volume251,400 shs
Average Volume453,110 shs
Market Capitalization$64.12 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.71

About Rexahn Pharmaceuticals (NYSEAMERICAN:RNN)

Rexahn Pharmaceuticals logoRexahn Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company's clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance. RX-3117 is a small molecule nucleoside compound with an anti-metabolite mechanism of action and has therapeutic potential in a range of cancers, including pancreatic, bladder, colon and lung cancer. Supinoxin is a small molecule inhibitor of phosphorylation of p68. The Company also has a drug candidate RX-21101, an N-(2-Hydroxypropyl) methacrylamide-docetaxel-folate, in pre-clinical development. The Company is working on research technologies, including multi-target aimed ligands platform and nano-based drug delivery systems.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: N/A
  • Symbol: NYSEAMERICAN:RNN
  • Previous Symbol: NYSEMKT:RNN
  • CUSIP: N/A
  • Web: rexahn.comcms
Profitability:
  • Trailing EPS: ($0.93)
  • Return on Equity: 44.61%
  • Return on Assets: 15.94%
Misc:
  • Outstanding Shares: 31,730,000
 

Frequently Asked Questions for Rexahn Pharmaceuticals (NYSEAMERICAN:RNN)

What is Rexahn Pharmaceuticals' stock symbol?

Rexahn Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "RNN."

How were Rexahn Pharmaceuticals' earnings last quarter?

Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) announced its quarterly earnings data on Monday, August, 8th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.02) by $0.01. View Rexahn Pharmaceuticals' Earnings History.

Where is Rexahn Pharmaceuticals' stock going? Where will Rexahn Pharmaceuticals' stock price be in 2017?

5 equities research analysts have issued twelve-month target prices for Rexahn Pharmaceuticals' shares. Their forecasts range from $13.00 to $19.50. On average, they anticipate Rexahn Pharmaceuticals' share price to reach $16.50 in the next twelve months. View Analyst Ratings for Rexahn Pharmaceuticals.

Are investors shorting Rexahn Pharmaceuticals?

Rexahn Pharmaceuticals saw a increase in short interest in October. As of October 31st, there was short interest totalling 2,106,770 shares, an increase of 28.0% from the October 13th total of 1,645,486 shares. Based on an average daily trading volume, of 673,912 shares, the days-to-cover ratio is presently 3.1 days. Currently, 6.8% of the company's stock are short sold.

Who are some of Rexahn Pharmaceuticals' key competitors?

Who are Rexahn Pharmaceuticals' key executives?

Rexahn Pharmaceuticals' management team includes the folowing people:

  • Peter C. Brandt, Independent Chairman of the Board (Age 59)
  • Peter D. Suzdak Ph.D., Chief Executive Officer, Director (Age 57)
  • Tae Heum Jeong, Chief Financial Officer, Secretary (Age 45)
  • Ely Benaim, Chief Medical Officer (Age 55)
  • Charles G. Beever, Independent Director (Age 63)
  • Mark P. Carthy, Independent Director (Age 55)
  • Kwang Soo Cheong Ph.D., Independent Director (Age 55)
  • Richard J. Rodgers, Independent Director (Age 50)

Who owns Rexahn Pharmaceuticals stock?

Rexahn Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Zurcher Kantonalbank Zurich Cantonalbank (0.16%). View Institutional Ownership Trends for Rexahn Pharmaceuticals.

Who bought Rexahn Pharmaceuticals stock? Who is buying Rexahn Pharmaceuticals stock?

Rexahn Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Zurcher Kantonalbank Zurich Cantonalbank. View Insider Buying and Selling for Rexahn Pharmaceuticals.

How do I buy Rexahn Pharmaceuticals stock?

Shares of Rexahn Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Rexahn Pharmaceuticals' stock price today?

One share of Rexahn Pharmaceuticals stock can currently be purchased for approximately $2.11.

How big of a company is Rexahn Pharmaceuticals?

Rexahn Pharmaceuticals has a market capitalization of $64.12 million.

How can I contact Rexahn Pharmaceuticals?

Rexahn Pharmaceuticals' mailing address is 15245 Shady Grove Rd Ste 455, ROCKVILLE, MD 20850-7203, United States. The company can be reached via phone at +1-240-2685300.


MarketBeat Community Rating for Rexahn Pharmaceuticals (NYSEAMERICAN RNN)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  161 (Vote Outperform)
Underperform Votes:  105 (Vote Underperform)
Total Votes:  266
MarketBeat's community ratings are surveys of what our community members think about Rexahn Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Rexahn Pharmaceuticals (NYSEAMERICAN:RNN)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 5 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $16.50

Consensus Price Target History for Rexahn Pharmaceuticals (NYSEAMERICAN:RNN)

Price Target History for Rexahn Pharmaceuticals (NYSEAMERICAN:RNN)

Analysts' Ratings History for Rexahn Pharmaceuticals (NYSEAMERICAN:RNN)

Show:
DateFirmActionRatingPrice TargetDetails
11/6/2017HC WainwrightReiterated RatingBuy$19.50View Rating Details
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$13.00View Rating Details
8/7/2017Ifs SecuritiesReiterated RatingOutperformView Rating Details
6/9/2017Rodman & RenshawReiterated RatingBuy$19.50View Rating Details
6/1/2017FBR & CoReiterated RatingOutperform$30.00 -> $14.00View Rating Details
2/29/2016Roth CapitalReiterated RatingBuy$1.75View Rating Details
(Data available from 11/21/2015 forward)

Earnings

Earnings History and Estimates Chart for Rexahn Pharmaceuticals (NYSEAMERICAN:RNN)

Earnings by Quarter for Rexahn Pharmaceuticals (NYSEAMERICAN:RNN)

Earnings History by Quarter for Rexahn Pharmaceuticals (NYSEAMERICAN RNN)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2016Q216($0.02)($0.01)ViewN/AView Earnings Details
5/9/2016Q116($0.02)($0.02)ViewN/AView Earnings Details
11/3/2015Q315($0.03)($0.02)ViewN/AView Earnings Details
8/10/2015Q215($0.03)($0.02)ViewN/AView Earnings Details
4/6/2015($0.03)($0.01)ViewN/AView Earnings Details
3/17/2015($0.02)($0.02)ViewN/AView Earnings Details
11/14/2014($0.03)($0.02)ViewN/AView Earnings Details
8/14/2014Q214($0.02)($0.02)ViewN/AView Earnings Details
3/25/2014($0.06)($0.01)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Rexahn Pharmaceuticals (NYSEAMERICAN:RNN)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Rexahn Pharmaceuticals (NYSEAMERICAN:RNN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Rexahn Pharmaceuticals (NYSEAMERICAN RNN)

Insider Trades by Quarter for Rexahn Pharmaceuticals (NYSEAMERICAN:RNN)
Institutional Ownership by Quarter for Rexahn Pharmaceuticals (NYSEAMERICAN:RNN)

Insider Trades by Quarter for Rexahn Pharmaceuticals (NYSEAMERICAN RNN)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/10/2017Chang Ho AhnDirectorSell250,000$0.70$175,000.00View SEC Filing  
1/12/2015Chang Ho AhnDirectorSell314,656$0.91$286,336.96View SEC Filing  
1/12/2015Tae Heum JeongCFOSell317,272$0.91$288,717.52View SEC Filing  
6/12/2014Chang Ho AhnDirectorSell136,193$0.99$134,831.07View SEC Filing  
9/9/2013Tae Heum JeongCFOSell71,139$0.46$32,723.94View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Rexahn Pharmaceuticals (NYSEAMERICAN RNN)

Source:
No headlines for this company have been tracked by MarketBeat.com

Social Media

Social activity is not available for this stock.

Financials

Chart

Rexahn Pharmaceuticals (NYSEAMERICAN RNN) Chart for Tuesday, November, 21, 2017
Loading chart…

This page was last updated on 11/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.